Supernus Pharmaceuticals reported $73.97M in Selling and Administration Expenses for its fourth fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Selling And Administration Expenses Change
Abbott ABT:US USD 2.83B 98M
Ani Pharmaceuticals ANIP:US USD 33.19M 3.11M
Aurora Cannabis Inc ACB:CN CAD 44.57M 476K
Bristol Myers Squibb BMY:US USD 2.27B 336M
Canopy Growth Corp WEED:CN CAD 120.51M 5.23M
Cara Therapeutics CARA:US USD 6.4M 484K
Corcept Therapeutics CORT:US USD 42.32M 7.16M
Eisai 4523:JP JPY 92.58B 4.5B
Eli Lilly And LLY:US USD 1.64B 29M
Endo International Ordinary Shares ENDP:US USD 192.46M 10.92M
Horizon Pharma HZNP:US USD 372.53M 25.03M
Lannett LCI:US USD 18.32M 1.62M
Marinus Pharmaceuticals MRNS:US USD 14.66M 1.27M
Pacira Pharmaceuticals PCRX:US USD 63.97M 2.69M
Perrigo Ordinary Shares PRGO:US USD 308.6M 27.6M
Pfizer PFE:US USD 4.87B 1.33B
Revance Therapeutics RVNC:US USD 63.54M 548K
Supernus Pharmaceuticals SUPN:US USD 73.97M 38.34M
Teva Pharmaceutical Industries TEVA:US USD 837M 60M
United Therapeutics UTHR:US USD 152M 53.6M
Xeris Pharmaceuticals Inc XERS:US USD 34.36M 34K